Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpayVac is a single-dose, long-acting immunocontraceptive vaccine used primarily for controlling fertility in wildlife, livestock, and companion animals. Its main active ingredient is porcine zona pellucida (pZP) or other zona pellucida antigens, delivered using a patented liposome-based delivery platform (such as VacciMax or DepoVax) that enhances immunogenicity and longevity by gradually releasing the antigen to the immune system[1][6][10]. After injection, SpayVac stimulates an antibody response against the zona pellucida membrane surrounding the egg, thereby blocking sperm binding and preventing fertilization. This immune response is robust, tissue-specific, and can last for multiple years without the need for booster shots[1][6][10]. Developed for use in feral horses, deer, seals, domestic cats, and aquaculture species, SpayVac represents a humane, non-surgical approach to animal population control, with applications currently under regulatory review for feral horses and deer[5][9][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SpayVac.